Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. (INTI) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001042418 · INTI · OTC · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001042418 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Inhibitor Therapeutics, Inc. (OTC: INTI) has submitted 715 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001042418, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Inhibitor Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Inhibitor Therapeutics, Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical INTI 10-K annual reports are available from 1997 through 2026.
Investors researching Inhibitor Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
INTI SEC Filings · 8 questionsInhibitor Therapeutics, Inc. (INTI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 715 filings and access original documents at no cost. Inhibitor Therapeutics, Inc.'s CIK is 0001042418.